Biosynex: 9% sales growth by 2024

(CercleFinance.com) - Biosynex has announced sales of 101.
4 million euros for 2024, up 9%, driven by dynamic export sales (+20%) and the resilience of the pharmaceuticals division, which grew by 7%.

The European diagnostics division was down 3%, mainly due to the domestic market as a result of lower Covid-19 sales, whereas sales in the USA diagnostics division climbed by 46%.

Larry Abensur, CEO, also emphasized the Group's restructuring efforts in 2024, and said he was "confident that the new year 2025 will see a return to profitable and sustainable growth in both core businesses".

Copyright (c) 2025 CercleFinance.com. All rights reserved.